For research and educational purposes only. Not medical advice.
Protocol builder — Pro tool overview
Protocol builder overview. Assemble a multi-compound stack, overlay normalized PK curves, screen peptide-to-peptide and peptide-to-medication interactions, and roll up monthly cost. Pro tool. Educational, not medical advice.
Summary
Stack assembly with PK overlay, peptide-interaction screen, and monthly cost rollup.
What this tool does
Assemble a stack of peptide and GLP-1 compounds. Normalized percent-of-peak PK overlays let you see how the compounds compose across a dosing window. Peptide-to-peptide and peptide-to-medication interaction flags surface from a cited static table. Monthly cost rollup uses entered per-vial cost inputs.
How the interaction screen works
The interaction table is static and hand-curated against the published peptide pharmacology literature. Medication-context rows cover insulin, sulfonylureas, narrow-therapeutic-index oral medicines, and anticoagulation. Peptide-to-peptide flags surface mechanism-of-action overlaps that warrant prescriber discussion (e.g., incretin duplication when stacking semaglutide and tirzepatide, or GH-axis secretagogues alongside somatropin).
What the tool will not do
It does not prescribe, recommend, or rank stacks. It does not check labs, lipids, or cardiovascular safety. The cost rollup uses inputs you provide, not market prices. The interaction screen is a discussion aid, not a clinical alert system.
Inputs the tool takes
- Compounds in the stack (2 to 8)
- Dose and frequency per compound
- Optional cost inputs per compound
- Optional medication-context flags (insulin, sulfonylureas, etc.)
What the tool returns
- Normalized PK overlay across the stack
- Peptide-to-peptide and peptide-to-medication interaction flags
- Monthly cost rollup (web only; suppressed on native per Apple 3.1.1 / Play Billing posture)
- Cited references for every flagged interaction
Cited literature
- Wegovy (semaglutide) FDA label
- Ozempic (semaglutide) FDA label
- Mounjaro (tirzepatide) FDA label
- Tesamorelin / Egrifta clinical literature (Falutz 2007 NEJM)
Interaction table hand-curated · cited references in builderContent.ts and PRO_TOOLS.md.
See it in action
The protocol builder is a pepSmart Pro tool. See what Pro includes.